Sarilumab
- Generic Name
- Sarilumab
- Brand Names
- Kevzara
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1189541-98-7
- Unique Ingredient Identifier
- NU90V55F8I
- Background
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approva...
- Indication
Sarilumab is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs); and adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tole...
- Associated Conditions
- Polymyalgia Rheumatica (PMR), Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 369
- Registration Number
- NCT02332590
- Locations
- 🇺🇸
Investigational Site Number 840403, Saint Petersburg, Florida, United States
🇺🇸Investigational Site Number 840229, Coral Gables, Florida, United States
🇺🇸Investigational Site Number 840140, Tampa, Florida, United States
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT02097524
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 217
- Registration Number
- NCT02057250
- Locations
- 🇨🇱
Investigational Site Number 152050, Santiago, Chile
🇨🇱Investigational Site Number 152007, Viña Del Mar, Chile
🇲🇽Investigational Site Number 484005, Monterrey, Mexico
Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 58
- Registration Number
- NCT01900431
- Locations
- 🇺🇸
Investigational Site Number 840007, Cleveland, Ohio, United States
🇹🇷Investigational Site Number 792004, Izmir, Turkey
🇹🇷Investigational Site Number 792006, Izmir, Turkey
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 776
- Registration Number
- NCT01764997
- Locations
- 🇺🇸
Investigational Site Number 840203, Washington, D.C., District of Columbia, United States
🇦🇷Investigational Site Number 032009, Zarate, Argentina
🇨🇱Investigational Site Number 152018, Santiago, Chile
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 546
- Registration Number
- NCT01709578
- Locations
- 🇺🇸
Investigational Site Number 840018, Idaho Falls, Idaho, United States
🇺🇸Investigational Site Number 840058, Columbia, South Carolina, United States
🇺🇸Investigational Site Number 840124, Clarksburg, West Virginia, United States
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT01217814
- Locations
- 🇲🇽
Investigational Site Number 484008, Durango, Mexico
🇨🇴Investigational Site Number 170004, Barranquilla, Colombia
🇨🇴Investigational Site Number 170005, Barranquilla, Colombia
Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 223
- Registration Number
- NCT01118728
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1675
- Registration Number
- NCT01061736
- Locations
- 🇦🇷
Investigational Site Number 032002, Cordoba, Argentina
🇦🇷Investigational Site Number 032004, Tucuman, Argentina
🇦🇷Investigational Site Number 032003, Córdoba, Argentina
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 301
- Registration Number
- NCT01061723
- Locations
- 🇺🇸
Investigational Site Number 840027, Los Angeles, California, United States
🇺🇸Investigational Site Number 840009, Boca Raton, Florida, United States
🇺🇸Investigational Site Number 840015, Boise, Idaho, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.